Unlock the Key TPD Insights from ASCO 2026
Drawing on a wide range of presentations at ASCO 2026, our analysts identified 91 TPD-relevant abstracts, with activity largely concentrated in clinical-stage and late-phase development, and translated this volume of data into clear, decision-ready insights, helping you quickly pinpoint where innovation is gaining momentum, which assets are advancing, and how the competitive landscape is evolving.
The report includes:
- 91 TPD-relevant abstracts reviewed, spanning 88 clinical and 3 preclinical studies
- A structured view of activity across trial phases, highlighting the progression of assets through the pipeline
- Insight into the most active drugs and sponsors, covering both established therapies and emerging contenders
- A breakdown of innovation across modalities, including SERDs, PROTACs, CELMoDs, and other next-generation approaches
- Quick-reference summaries for every abstract, with links to support deeper investigation
You May Also Be Interested In…
Learn More About TPD
- The Most Comprehensive Way to Search the TPD Drug Development Landscape: Unique search ontologies based on TPD drug and trial characteristics
- Market Leading Approach to TPD Preclinical & Clinical Data Curation: Manual curation of key TPD research and development data points by TPD research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search TPD company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
